This Just In…
Two new pharmacy benefit management companies have decided to enter the market, promising to facilitate greater drug price transparency: EmsanaRx and the Mark Cuban Cost Plus Drug Company.
Pharmacy benefit managers (PBMs) work with insurance companies, pharmacies, and manufacturers to negotiate the lowest drug costs for their members. Drug Channels Institute estimates that in 2020 about 77 percent of all prescription claims ran through the top three PBMs — CVS Health, the Express Scripts business of Cigna, and the OptumRx business of UnitedHealth Group.
EmsanaRx is a nonprofit coalition of almost 40 companies planning to offer pharmacy benefit management services to employers. EnsanaRx, which includes retailers such as Walmart and Costco, is the PBM unit of the Purchaser Business Group on Health (PBGH) coalition. Emsana Health plans to serve as an “innovation studio” which will develop new products and solutions with input from PBGH’s employer members.
The goal of the Mark Cuban Cost Plus Drug Company is to sell generic drugs at a transparent, fixed rate, and to unite manufacturing, distribution, and pharmacy services under one roof. The PBM plans to be running by 2023, according to an article in the Wall Street Journal.
Copyright © 2020 Smarts Publishing
About the Author
Share This Story
Related Blogs
Hidden Risks of Summer School: Operational Safety Strategies Schools Can’t Ignore
Summer school risk management is essential to ensuring student [...]
Employers Expand Family Benefits Amid Reproductive Health Concerns
Recent surveys indicate heightened anxiety among many U.S. employees planning to conceive or adopt children. This follows the 2024 election results and ongoing legal developments regarding reproductive rights. Over half of respondents want their employers to publicly support continued access to comprehensive family planning services.
Companies Could Face Fines Over Retirement Plan Mismanagement
A recent analysis of government retirement plan filings suggests companies across the country could be falling short in properly managing their employees' 401(k) and 403(b) plans, exposing them to the possibility of regulatory fines and penalties.